CREO Stock Overview
Creo Medical Group PLC, through its subsidiaries, engages in the research and development of electrosurgical medical devices relating to the field of surgical endoscopy in the United Kingdom.
Creo Medical Group PLC Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£0.39|
|52 Week High||UK£1.79|
|52 Week Low||UK£0.38|
|1 Month Change||-14.37%|
|3 Month Change||-43.43%|
|1 Year Change||-71.82%|
|3 Year Change||-78.77%|
|5 Year Change||-44.25%|
|Change since IPO||-51.56%|
Recent News & Updates
|CREO||GB Medical Equipment||GB Market|
Return vs Industry: CREO underperformed the UK Medical Equipment industry which returned -11.3% over the past year.
Return vs Market: CREO underperformed the UK Market which returned -7% over the past year.
|CREO Average Weekly Movement||3.6%|
|Medical Equipment Industry Average Movement||6.6%|
|Market Average Movement||5.9%|
|10% most volatile stocks in GB Market||11.1%|
|10% least volatile stocks in GB Market||2.9%|
Stable Share Price: CREO is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: CREO's weekly volatility (4%) has been stable over the past year.
About the Company
Creo Medical Group PLC, through its subsidiaries, engages in the research and development of electrosurgical medical devices relating to the field of surgical endoscopy in the United Kingdom. It is developing Croma, an energy platform that powers a suite of multi-modal devices to optimize treatments for patients and physicians. The company also offers Speedboat Inject, an energy multimodality instrument for flexible endoscopy; Speedboat Slim, a flexible bipolar RF and microwave device for cutting and coagulation; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a flexible microwave ablation device; SlypSeal Flex, a flexible haemostasis device for the treatment of upper and lower GI bleeds; SpydrBlade Flex, a flexible bipolar RF and microwave scissor device that grasps, cuts and, coagulates highlyperfused tissues; and endotherapy accessories.
Creo Medical Group PLC Fundamentals Summary
|CREO fundamental statistics|
Is CREO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CREO income statement (TTM)|
|Cost of Revenue||UK£13.89m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.16|
|Net Profit Margin||-108.63%|
How did CREO perform over the long term?See historical performance and comparison